The Centers for Medicare & Medicaid Services this week released for comment a proposal that Medicare cover diagnostic laboratory tests that use Next Generation Sequencing for patients with a breast or ovarian cancer that may be inherited. The test used must be approved by the Food and Drug Administration, ordered by a treating physician for a patient not previously tested using NGS, and performed in a laboratory certified under the Clinical Laboratory Improvement Amendments program, among other requirements. Under the proposal, Medicare administrative contractors also could decide to cover the tests for patients with other cancers that may be inherited.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services released a memo Dec. 16 announcing the agency’s intent to conduct a voluntary pilot in 2026, called the…
Headline
The Centers for Medicare & Medicaid Services Dec. 15 published the Measures Under Consideration List for 2025. These are measures that CMS is considering…
Headline
The Medicare Payment Advisory Commission Dec. 4 and 5 discussed draft payment update recommendations for 2027, which the commission will vote on in January.…
Headline
The House Dec. 1 passed the Hospital Inpatient Services Modernization Act (H.R. 4313), legislation extending certain Medicare waivers authorizing the hospital-…
Headline
The Centers for Medicare & Medicaid Services announced Dec. 1 that it intends to expand the Inpatient Rehabilitation Facility Review Choice Demonstration…
Headline
The Centers for Medicare & Medicaid Services Nov. 25 announced lower prices for 15 Medicare Part D drugs selected for the second cycle of negotiations…